osteoprotegerin has been researched along with Deficiency-Diseases* in 2 studies
1 trial(s) available for osteoprotegerin and Deficiency-Diseases
Article | Year |
---|---|
Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study.
To investigate the effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs, iliac crest bone biopsies were obtained from 25 patients with GH deficiency (9 women and 16 men; ages, 21-61 yr; mean, 46 yr) who were randomized to sc injections with GH (2 IU/m(2).d) or placebo for 12 months. Levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-3, IGFBP-5, osteocalcin, OPG, RANKL, and total protein were determined in extracts obtained after EDTA and guanidine hydrochloride extraction. Calcium was determined after HCl hydrolysis. Comparing changes during GH or placebo treatment, significant increases were observed during GH substitution for cortical and trabecular bone content of IGF-I [mean difference vs. placebo (mean +/- SEM), 97 +/- 30 and 72 +/- 38%] and OPG (mean difference vs. placebo, 109 +/- 59 and 51 +/- 19%). Also, a significant decline was found for cortical osteocalcin (mean difference vs. placebo, -49 +/- 22%) during GH treatment. In conclusion, our results indicate that long-term GH treatment increases the accumulation of IGF-I and OPG in cortical and trabecular bone in patients with GH deficiency, and this may in turn lead to an increase in bone mass and improved skeletal biomechanical competence. Topics: Adult; Bone and Bones; Deficiency Diseases; Double-Blind Method; Female; Glycoproteins; Human Growth Hormone; Humans; Male; Middle Aged; Osteocalcin; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Somatomedins; Time Factors | 2002 |
1 other study(ies) available for osteoprotegerin and Deficiency-Diseases
Article | Year |
---|---|
Calcium and Magnesium Supplementation Improves Serum OPG/RANKL in Calcium-Deficient Ovariectomized Rats.
Magnesium (Mg) deficiency has been reported to result in increases in bone resorption through changes in the cytokine system, such as decreases in serum osteoprotegerin (OPG) concentrations and increases in receptor activator of NF-κB ligand (RANKL) concentrations. However, there are few data about the effects of Mg supplementation on OPG and RANKL. This study was carried out to investigate the effects of Mg supplementation on bone mineral density (BMD), bone mineral content (BMC), serum OPG, and RANKL in ovariectomized (OVX) rats relative to calcium (Ca) intake levels. Fifty-five Sprague-Dawley female rats were divided into the following five groups and fed for 12 weeks as indicated: sham-operated control group (sham), OVX Ca-deficient group (OLCa, 0.1% Ca and 0.05% Mg), OVX Ca-deficient and Mg-supplemented group (OLCaMg, 0.1% Ca and 0.1% Mg), OVX Ca-adequate group (OACa, 0.5% Ca and 0.05% Mg), and OVX Ca-adequate and Mg-supplemented group (OACaMg, 0.5% Ca and 0.1% Mg). The BMD of the lumbar spine, femur, and tibia in the OVX groups was significantly lower than that in the sham group. The OVX group with an adequate-Ca diet showed significantly higher BMC of the lumbar spine compared to the low Ca-diet group regardless of Mg supplementation. The OACaMg group had significantly higher levels of OPG and OPG/RANKL ratio than did the OLCa group. From the above results, it is still unclear whether Mg supplementation can improve bone mineral status, while Mg supplementation with an adequate-Ca diet resulted in a change in cytokines that may promote bone formation. Topics: Animals; Bone Density; Calcium; Calcium Carbonate; Calcium, Dietary; Deficiency Diseases; Drug Synergism; Female; Magnesium Oxide; Osteoprotegerin; Ovariectomy; RANK Ligand; Rats; Rats, Sprague-Dawley | 2010 |